Albert Beraldo
Director/Board Member at MEDICENNA THERAPEUTICS CORP.
Net worth: 445 250 $ as of 2024-03-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Fahar Merchant | M | - |
Medicenna Therapeutics, Inc.
Medicenna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Medicenna Therapeutics, Inc. develops and commercializes therapeutics for the treatment of central nervous system and urological cancers. It also develops proprietary therapeutic cytokines called Superkines, Superkines is powerful immune-system modulators that have significant therapeutic potential for the treatment of many forms of cancer and selected other diseases. Superkines can be fused to tumor cell-killing payloads to form Medicenna's proprietary Empowered Cytokines (EC's). The firm's EC's are being developed for the targeted treatment of cancer and are potentially vastly superior alternatives to other targeted cancer therapies such as Antibody Drug Conjugates. The company was founded by Fahar Merchan and Rosemina Merchant in 2011 and is headquartered in Vancouver, CA. | 12 years |
Rosemina Merchant | F | - |
Medicenna Therapeutics, Inc.
Medicenna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Medicenna Therapeutics, Inc. develops and commercializes therapeutics for the treatment of central nervous system and urological cancers. It also develops proprietary therapeutic cytokines called Superkines, Superkines is powerful immune-system modulators that have significant therapeutic potential for the treatment of many forms of cancer and selected other diseases. Superkines can be fused to tumor cell-killing payloads to form Medicenna's proprietary Empowered Cytokines (EC's). The firm's EC's are being developed for the targeted treatment of cancer and are potentially vastly superior alternatives to other targeted cancer therapies such as Antibody Drug Conjugates. The company was founded by Fahar Merchan and Rosemina Merchant in 2011 and is headquartered in Vancouver, CA. | 13 years |
Andrew L. Strong | M | 57 |
Medicenna Therapeutics, Inc.
Medicenna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Medicenna Therapeutics, Inc. develops and commercializes therapeutics for the treatment of central nervous system and urological cancers. It also develops proprietary therapeutic cytokines called Superkines, Superkines is powerful immune-system modulators that have significant therapeutic potential for the treatment of many forms of cancer and selected other diseases. Superkines can be fused to tumor cell-killing payloads to form Medicenna's proprietary Empowered Cytokines (EC's). The firm's EC's are being developed for the targeted treatment of cancer and are potentially vastly superior alternatives to other targeted cancer therapies such as Antibody Drug Conjugates. The company was founded by Fahar Merchan and Rosemina Merchant in 2011 and is headquartered in Vancouver, CA. | 5 years |
Karen Dawes | F | 72 | 5 years | |
Jane E. Pagel | M | - | 6 years | |
Jack Geltosky | M | 78 | 4 years | |
Delphine Davan | F | - | 1 years | |
John Sampson | M | - | 3 years | |
Eamonn Peters | M | - | 1 years | |
David Hyman | M | - | - | |
Evelyn Pau | M | - | 1 years | |
Michael Lavergne | M | - | 6 years | |
Minh To | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
Statistics
Country | Connections | % of total |
---|---|---|
Canada | 44 | 84.62% |
United States | 9 | 17.31% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Albert Beraldo
- Personal Network